CIA-RDP96-00788R001500110001-4

-
Approved For Release 20
CODET
GURTYJA-RDP96-00788R001500110001-4
1.
(S/NOFORN-CL)
GENERAL
1.1
The objective of this effort is to investigate a particular aspect
of the psychoenergetic phenomena known as remote viewing that has potential
military intelligence application. Coordinate Remote Viewing (CRV) is a
staged technique which utilizes coordinates to facilitate acquisition of a
remote viewing target.
1.2 Major goals are the determination if CRV technology can be successfully
transferred to INSCOM personnel with a corresponding increase in the reliability
of a remote viewer.
2. (S/NOFORN-CL)
SPECIFIC TASK
2.1
Train army personnel in CRV Stages III and IV.
2.1.1
Initiate training at the highest skill level (CRV Stage) of the
trainee.
2.1.2
Training for each CRV stage will normally be divided into three
two week working sessions.
The Session dates will be mutually agreed to by SRI
and INSCOM.
2.1.3
After successful completion of CRV Stage III, schedule the trainee
to begin
CRV Stage IV.
2.2
Determine the potential of the trainee for further training.
3.
(U)
SECURITY
Military security requirements in the performance of this contract shall be
maintained in accordance with DD Form 254 attached hereto. The highest
classification
involved in the performance of this contract is SECRET-
NO FOREIGN DISSEMINATION.
4.
(S/NOFORN-CL)
DELIVERABLES:
The contractor will provide the following.
4.1
State-of-The-Art CRV training.
4.2
Progress report (2 copies): Written evaluation of trainee progress
at the completion of each two week working session.
4.3
Final Report:
4.3.1
A final report in 3 copies will be furnished within 30 days
after completion of the CRV stage.
4.3.2
Report will include a summary of the training presented; an
evaluation of the trainee's ability to understand the training; and a summary
of the trainee's accomplishments during the training period.
4.3.3
Report should also include an evaluation of the trainee's
future remote viewing capabilities, and a recommendation concerning further
training.
wApproved ForRelease 2001/04/03 ℃
RDP96-00788R001500110001-4
INTELLIGENCE SOURCES AND
METHODS INVOLVED
YOLY
SE
ULUNLT
NOT RELEASABLE TO FOREIGN NATIONALS
.

Approved For Release 2001/04/02 1014-FDP96-00788R001500110001-4
5. (S/NOFORN-CL) POST TRAINING ACCESS: After the completion of each CRV
training stage personnel involved in the training program will have
reasonable access to INSCOM personnel trained to assist in further evaluation of
CRV.
6.
(U)
SPECIAL REUQIREMENTS
6.1
Use of human subjects
(a)
The following definitions are used:
(1) At risk means that the human subject may be exposed to the
possibility of harm - physical, biological, psychological, sociological, or other
as
a consequence of an act or omission that goes beyond the application
of those established and accepted methods or procedures which are in his
best interests, or that increases ordinary risks of daily life, including the
recognized risks inherent in his chosen occupation or field of service.
(2) Human subject means any human being who, knowingly or unknowingly,
is subjected to an act or omission, whether at risk or not, the object of
which is to contribute to knowledge to be gained as a part of work to be
performed under the scope of this contract.
(b) The contractor, before undertaking to perform any study involving
human subjects, whether at risk or not, shall insure that the following minimum
conditions are complied with:
(1) The proposed study has been reviewed and approved by a committee
meeting the requirements set forth in Chapter 46 of Title 45 of the Code of
Federal Regulations.
(2)
The number of human subjects used will be kept to the minumum number
that will reasonably achieve the required results.
(3) The study must be such as to contribute significantly to scientific
knowledge and have reasonable prospects of yielding important results essential
to an Army research program.
(4) The study will be conducted only by persons possessing the
requisite scientific qualifications. The highest degree of skill and care
will be required during all stages of study of persons who conduct or assist
in the study.
(5) The human subject will be informed that at any time during the
course of his participation he has the right to revoke his consent and
withdraw from participation without prejudice to himself.
(6) Participation by subjects will be immediately terminated if it
subsequently appears that the risk to the subjects is significantly greater
than anticipated at the time review and approval was granted.
Approved For Release 2001/04/021:@ADP96-00788R001500110001-4
INTELLIGENCE SOURCES AND
NOT RELEASABLE TO FOREIGN NATIONALS
METHODS INVOLVED
2

Approved For Release 2001/044
SEADET
VLOTET: 00-00788R001500110001-4
(7) There shall be no greater intrusion into the privacy of the
human subject tban is absolutely necessary for the conduct of the study
involved. . Except for the submission of reports and other data required by
this contract, any information obtained about human subjects as a result of
participation shall be held as confidential as the law allows.
(8) The study will be conducted so as to avoid all unnecessary
physical or mental suffering or injury.
(9) No study will be conducted if there is any inherent reason to
believe that death or disabling injury is likely to occur. Sufficient
animal or laboratory experiments, or other evaluations, must have been completed
to give assurance of acceptable risks prior to the use of human subjects.
(10) The degree of risk to be taken will never exceed that which is
justified by the benefit to the subject and/or the humanitarian importance
of the knowledge to be gained.
(11) A physician will be responsible for the medical care of
subjects. . Even if not the project leader, the physician will have authority
to terminate the study at any time that he believes death, injury or harm
is likely to result.
(12) Proper preparations will be made, and adequate facilities provided
to protect the subject against all foreseeable possibilities if injury,
disability or death. This includes but is not limited to hospitalization
and medical treatment as may be required. In addition, all apparatus and
instruments necessary to deal with likely emergency situations will be
available.
(13) Human subjects will have no physical or mental conditions which
will make participation more hazardous for them than it would be for normal
healthy persons, unless such condition is a necessary prerequisite for the
particular study involved. In any such case, the use of human subjects with
such pre-existing conditions must have been specifically described and
justified in the scope of the work to be performed under this contract.
(14) The scientifically qualified person conducting the study,
and each member of his research team, will be prepared to terminate the
subject's participation at any stage if he has reason to believe, in the
exercise of the good faith, superior skill, and careful judgement required of
him, that continuation is likely to result in injury, disability, or death
to the human subject.
(c) The contractor, before permitting any person to participate
as a human subject, whether at risk or not, shall insure that the following
minimum conditions are complied with:
(1) Legally effective informed consent will be obtained by adequate
and appropriate methods in accordance with the provisions of this clause.
SECRET
ULUNILI
SENSITIVE
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110001-4
INTELLIGENCE SOURCES
METHODS INVOLVED
NOT RELEASABLE TO FOREIGN NATIONALS

-
Approved For Release 200114ADET
OLDINTYP: 30-00788R001500110001-4
(2)
All consent must be voluntary. It must be the knowing consent.
of the individual or his legally authorized representative, so situated as
to be able to exercise free power of choice without there having been any
use of force, fraud, deceit, duress, constraint, coercion, or lawful or
improper inducement. The elements of information necessary to such consent
include:
(i) A fair explanation of the procedures to be followed, and their
purposes, including identification of any procedures which are experimental.
(ii) A description of any attendant discomforts or risks reasonably
to be anticipated.
(iii) A description of any benefits reasonably to be anticipated.
(iv) A disclosure of any appropriate alternative procedures that
might be advantagious to the subject.
(v) An offer to answer any questions concerning the procedure.
(vi) An instruction that the subject is free to revoke his consent
and to discontinue participation at any time without prejudice to himself.
(d) Exculpatory language through which the subject is made to
waive, or appear to waive, any of his legal rights, including any release
from liability for negligence, is prohibited.
(e) Prior consent by a subject or his legally authorized
representative shall be obtained in all cases.
Such consent shall be in
writing whenever it is reasonably possible to do so. The consent form
may be read to the subject or his legally authorized representative, but in
any event he or his legally authorized representative must be given adequate
opportunity to read it and to ask questions they might have.
This consent
form should then be signed by the subject or his legally authorized
representative and by a witness not directly involved in the study. Oral
consent may be used only when it has been specifically described and
justified in the scope of the work to be performed under this contract or
approved in writing by the contracting officer. When so authorized and used,
oral consent is subject to all the same standards as apply to written consent,
except that the signature of the subject or his legally authorized
representative is not required.
(f) Prior to conduct of the study, the contractor shall submit for
approval to the contracting officer's representative a detailed description
of the means by which informed consent will be obtained, to include any forms
to be used. Upon completion of the study, the contractor will submit
to the contracting officer's representative a detailed report demonstrating
compliance with paragraph (c), to include copies of the written consent if
such was obtained.
(g)
The contractor shall not undertake to conduct either the clinical
pharmacology or clinical trails of an investigational drug unless this
contract contains the clause entitled "Clinical Study of Investigational Drugs."
WAR Approved For Release 2004/04/02 001A-RDP96-00788R001500110001-4
INTELLIGENCE SOURCES AND
METHODS INVOLVED
NOT RELEASABLE TO FOREIGN NATIONALS

Approved For Release 2001/04/04
OLDET000788R001500110001-4
6.2 DoD Direcive 5240.1-R governing experimentation on human subjects
will be followed by the contractor. Informed consent of all subjects will
be obtained in writing in accordance with the guidelines issued by the
Department of Health, Education and Welfare. All persons participating
as human subjects, as defined in paragraph 6.1 above shall be known to
possess the abilities and qualities which will be observed and analyzed
during the conduct of this contract.
-
SF: SENSITIVE
Approved For Release 2001/040200AFRDP96.00788R001500110001-4
INTELLIGENCE SOURC
METHODS INVOLVED
NOT RELEASABLE TO FOREIGN NATIONALS

Approved For Release 2001/04/SEMDET06 0078
bo6.00788R001500110001-4
JUSTIFICATION FOR SOLE SOURCE PROCUREMENT
1. (S) SRI International is uniquely qualified for this sole source
procurement by virtue of a combination of experience and performance.
2. (S/NOFORN) SRI International is a recognized leader in the field of
psychoenergetics and has performed similar work for other U.S. Government
agencies over the past few years. Previous work, under DIA contracts
MDA-908-81-C-0292 and MDA-908-92-C-0034 has formed a highly meaningful data
base which will greatly enhance the value and effectiveness of this new
contractural effort.
3.
(S) The effort involved for a new contractor to research the same level
of capability and expertise that SRI currently possesses for this area would
be too time consuming and uneconomical to acquire and develop. To acquaint
a new contractor in this area of expertise, if he could be found, would
require several years simply to achieve the present level of expertise and
competence possessed by SRI International.
WARNING NOTICE: SENSITIVE
Approved For Release 2001/00/00 1: 5BP6 00788R001500110001.
METHODS INVOLVED
JIGNLT
NOT RELEASABLE TO FOREIGN NATIONALS